Wall Street analysts expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to announce ($0.91) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Aclaris Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.97) and the highest estimate coming in at ($0.81). Aclaris Therapeutics reported earnings per share of ($0.50) during the same quarter last year, which indicates a negative year-over-year growth rate of 82%. The company is scheduled to report its next earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that Aclaris Therapeutics will report full year earnings of ($3.21) per share for the current year, with EPS estimates ranging from ($3.36) to ($2.97). For the next financial year, analysts expect that the firm will report earnings of ($3.46) per share, with EPS estimates ranging from ($3.64) to ($3.30). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.12.

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $50.00 price objective on shares of Aclaris Therapeutics and gave the company a “buy” rating in a report on Wednesday. BidaskClub lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Jefferies Group LLC reissued a “buy” rating and set a $36.00 price objective on shares of Aclaris Therapeutics in a report on Monday, July 31st. Guggenheim reissued a “buy” rating and set a $40.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. Finally, ValuEngine raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $39.00.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/10/aclaris-therapeutics-inc-nasdaqacrs-expected-to-announce-earnings-of-0-91-per-share.html.

Aclaris Therapeutics (NASDAQ:ACRS) traded down 13.05% during trading on Thursday, hitting $23.45. The stock had a trading volume of 202,179 shares. The firm has a 50 day moving average of $27.89 and a 200-day moving average of $27.99. The stock’s market cap is $626.96 million. Aclaris Therapeutics has a 12 month low of $18.24 and a 12 month high of $33.25.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. increased its position in Aclaris Therapeutics by 109.7% in the second quarter. Alliancebernstein L.P. now owns 19,500 shares of the biotechnology company’s stock worth $529,000 after buying an additional 10,200 shares in the last quarter. Wells Fargo & Company MN increased its position in Aclaris Therapeutics by 230.8% in the second quarter. Wells Fargo & Company MN now owns 40,883 shares of the biotechnology company’s stock worth $1,109,000 after buying an additional 28,524 shares in the last quarter. Franklin Resources Inc. increased its position in Aclaris Therapeutics by 55.4% in the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after buying an additional 697,104 shares in the last quarter. Kennedy Capital Management Inc. acquired a new position in Aclaris Therapeutics during the second quarter worth about $2,033,000. Finally, Rosenblum Silverman Sutton S F Inc. CA increased its position in Aclaris Therapeutics by 17.3% in the second quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 38,400 shares of the biotechnology company’s stock worth $1,041,000 after buying an additional 5,650 shares in the last quarter. Institutional investors own 88.64% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.